Literature DB >> 17259943

The prospects for "personalized medicine" in drug development and drug therapy.

J Woodcock1.   

Abstract

There has been much recent discussion about the advent of "personalized medicine," but controversy exists over its exact definition; how, when, and whether it will be brought about, and what means could be used to measure its attainment. In fact, the concept of "personalized medicine" is a sort of shorthand used to represent the logical next steps in progression of medical science toward greater mechanistic understanding of health, disease, and treatment. This shorthand is attractive to the public because of its intuitive appeal, and irritating to the biomedical community because it glosses over the very real scientific and implementation challenges. This paper evaluates the trajectory and promise of these next steps for the currently problematic states of both drug development and therapy.

Mesh:

Year:  2007        PMID: 17259943     DOI: 10.1038/sj.clpt.6100063

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  39 in total

1.  The roadmap to personalized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

2.  Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

3.  Clinical and translational sciences: at the intersection of molecular and individualized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

4.  Translational medicine in the era of health care reform.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

5.  Experimental therapeutics: a paradigm for personalized medicine.

Authors:  Scott A Waldman; Walter K Kraft; Timothy J Nelson; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

Review 6.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 7.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

8.  Optical molecular imaging approach for rapid assessment of response of individual cancer cells to chemotherapy.

Authors:  Zhen Luo; Rohan Vijay Tikekar; Kiana Michelle Samadzadeh; Nitin Nitin
Journal:  J Biomed Opt       Date:  2012-10       Impact factor: 3.170

9.  A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Contemp Clin Trials       Date:  2013-04-11       Impact factor: 2.226

Review 10.  Combining targeted therapies: practical issues to consider at the bench and bedside.

Authors:  Jordi Rodon; Jose Perez; Razelle Kurzrock
Journal:  Oncologist       Date:  2010-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.